Marinus’ IV seizure drug faces efficacy questions as Ph3 continues past interim analysis

Mar­i­nus Phar­ma­ceu­ti­cals is con­tin­u­ing a Phase 3 tri­al of an in­tra­venous treat­ment for pro­longed seizures past an in­ter­im analy­sis, which sug­gests that the study did not meet sta­tis­ti­cal sig­nif­i­cance.

The com­pa­ny is study­ing an IV for­mu­la­tion of ganax­olone, a seizure drug it mar­kets as Ztalmy, in re­frac­to­ry sta­tus epilep­ti­cus — pro­longed seizures that do not re­spond to two lines of oth­er med­ica­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.